News | February 22, 2007

Now in Trial, Catheter-Based Device May Reduce Number of Surgeries for Congenital Heart Patients

Feb. 23, 2007 — The first patient implant was performed this week in a feasibility study evaluating the use Medtronic’s Melody Transcatheter Pulmonary Valve and Ensemble Transcatheter Delivery System to treat patients requiring congenital pulmonary heart valve replacement.

The prospective, non-randomized, feasibility clinical trial will enroll 30 patients at three U.S. medical centers including:

• Children's Hospital Boston (Boston, MA) with investigators James Lock, M.D. Cardiologist-in-Chief and Emile Bacha, M.D. Senior Associate in Cardiac Surgery

• Morgan Stanley Children's Hospital of New York - Presbyterian (New York, NY) with investigators Dr. William Hellenbrand, M.D. Director of Catheterization Laboratory for Congenital Heart Disease and Ralph Mosca, M.D. Director of Pediatric Cardiac Surgery

• Miami Children's Hospital (Miami, FL) with investigators Evan Zahn, M.D. Chief, Cardiology and Redmond Burke, M.D. Chief Cardiovascular Surgery

"We are excited about the promise of bringing this new, non-surgical procedure to the thousands of U.S. patients suffering from congenital heart disease with defects that disrupt the blood flow from the right ventricle to the pulmonary artery," said Dr. James Lock, Cardiologist-in-Chief at Children's Hospital Boston. "Our first implant has been conducted with positive results — both clinically and from a quality of life perspective — for the patient by delaying the need for an invasive open heart procedure to restore valve function."

"Effective management of congenital heart defects over a patient's lifetime requires dedicated collaboration between cardiac surgeons and interventional cardiologists," added Dr. John Mayer, Senior Associate in Cardiac Surgery at Children's Hospital Boston. "Together, members of these two disciplines draw on a variety of treatment options and clinical pathways. We hope that the Melody valve will be an important addition to the choices available for our patients."

The defect often requires open heart surgery early in life to implant a prosthetic or bioprosthetic valved-conduit to establish adequate blood flow from the heart to the lungs. However, the functional life span of these conduits is relatively limited, and as a result, most patients with this type of defect may require multiple open heart surgeries to place new valved conduits as they grow over their lifetime.

To meet this clinical need, Medtronic says it will use this trial to evaluate the Melody valve and Ensemble delivery system as a catheter-based alternative treatment in order to restore effective pulmonary valve function and potentially prolong the functional life of the right ventricle to pulmonary artery conduits. This alternative treatment is aimed at reducing the number of open heart surgeries these patients must undergo.

To date, more than 200 patients have been treated with the therapy. The Melody valve and Ensemble system are not currently available in the U.S., but Medtronic has received Canadian approval and CE Mark approval in Europe for commercial sale of the Medtronic Melody Transcatheter Pulmonary Valve and Ensemble Transcatheter Delivery System.

For more information visit www.medtronic.com.

Related Content

First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
Overlay Init